Luoxin Pharmaceuticals Group Stock Co., Ltd.(002793.SZ)
No price history available.
Key financial summary
Financials in CNY| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | CNYm | 6,096 | 6,478 | 3,588 | 2,364 | 2,647 | 2,273 | N/A | N/A |
| Operating profit | CNYm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net profit | CNYm | 321 | 406 | -1,225 | -661 | -965 | -289 | N/A | N/A |
| EPS reported | CNY | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating cashflow per share | CNY | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Capex per share | CNY | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF per share | CNY | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Free cash flow | CNYm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt | CNYm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Book value equity | CNYm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Book value per share | CNY | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Number of shares | m | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| DPS (TTM paid) | CNY | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
Financial summary
Financials in CNY| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/B LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/S LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/FCF LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EV/EBITDA LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EV/Sales LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Earnings Yield LTM | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF Yield | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Quality | |||||||||
| ROE | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| ROIC | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating margin | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Gross margin | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF/Sales | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Growth and momentum | |||||||||
| EPS Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Sales Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net Income Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating Profit Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Dividend and capital structure | |||||||||
| Dividend Yield | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Dividend Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Payout Ratio | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF/Debt | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net Debt/EBITDA | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EBIT/Net interest | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt/market cap | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt/Equity | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Gross debt/equity | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
Company overview
Luoxin Pharmaceuticals Group Stock Co., Ltd. is a Chinese pharmaceutical enterprise, primarily focused on the research, development, manufacture, and commercialization of pharmaceutical products. Headquartered in Linyi, the company offers an extensive portfolio of active pharmaceutical ingredients (APIs) and intermediates. These key components cater to a wide array of therapeutic areas, including antiviral and anti-infective treatments, respiratory and digestive system disorders, nervous and endocrine system conditions, cardiovascular health, oncology, and anti-allergy medications. Additionally, it supplies APIs and intermediates for antipyretic, analgesic, and anti-inflammatory drugs. Beyond its core pharmaceutical activities, Luoxin Pharmaceuticals also ventures into the provision of medical treatment and broader health services. The company adopted its current name, Luoxin Pharmaceuticals Group Stock Co., Ltd., in April 2020, having previously operated as Zhejiang Doyin Pump Industry Co., Ltd.
Similar companies
- China Shineway Pharmaceutical Group Limited
- Shenzhen Neptunus Bioengineering Co., Ltd.
- Suven Life Sciences Limited
- HPGC Renmintongtai Pharmaceutical Corporation
- Jiangsu Jibeier Pharmaceutical Co., Ltd.
- Sun Pharma Advanced Research Company Limited
- Teyi Pharmaceutical Group Co.,Ltd
- Shenzhen Weiguang Biological Products Co., Ltd.
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Luoxin Pharmaceuticals Group Stock Co., Ltd. (002793.SZ)
No price history available.
Not enough data to calculate KvantraRank
Based on consensus from external analysts. Not Kvantra's opinion.
Luoxin Pharmaceuticals Group Stock Co., Ltd. is a Chinese pharmaceutical enterprise, primarily focused on the research, development, manufacture, and commercialization of pharmaceutical products. Headquartered in Linyi, the company offers an extensive portfolio of active pharmaceutical ingredients (APIs) and intermediates. These key components cater to a wide array of therapeutic areas, including antiviral and anti-infective treatments, respiratory and digestive system disorders, nervous and endocrine system conditions, cardiovascular health, oncology, and anti-allergy medications. Additionally, it supplies APIs and intermediates for antipyretic, analgesic, and anti-inflammatory drugs. Beyond its core pharmaceutical activities, Luoxin Pharmaceuticals also ventures into the provision of medical treatment and broader health services. The company adopted its current name, Luoxin Pharmaceuticals Group Stock Co., Ltd., in April 2020, having previously operated as Zhejiang Doyin Pump Industry Co., Ltd.
- China Shineway Pharmaceutical Group Limited
- Shenzhen Neptunus Bioengineering Co., Ltd.
- Suven Life Sciences Limited
- HPGC Renmintongtai Pharmaceutical Corporation
- Jiangsu Jibeier Pharmaceutical Co., Ltd.
- Sun Pharma Advanced Research Company Limited
- Teyi Pharmaceutical Group Co.,Ltd
- Shenzhen Weiguang Biological Products Co., Ltd.